184 related articles for article (PubMed ID: 32082425)
1. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer.
Zhao B; Zhao H; Zhao J
Ther Adv Med Oncol; 2020; 12():1758835919895753. PubMed ID: 32082425
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
Shen X; Zhao B
BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.
Zhao B; Zhao H; Zhao J
Ther Adv Med Oncol; 2020; 12():1758835920937612. PubMed ID: 32728392
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD
J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847
[TBL] [Abstract][Full Text] [Related]
8. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.
Khunger M; Hernandez AV; Pasupuleti V; Rakshit S; Pennell NA; Stevenson J; Mukhopadhyay S; Schalper K; Velcheti V
JCO Precis Oncol; 2017 Nov; 1():1-15. PubMed ID: 35172490
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
Huang Q; Zheng Y; Gao Z; Yuan L; Sun Y; Chen H
J Cancer; 2021; 12(4):1133-1143. PubMed ID: 33442411
[No Abstract] [Full Text] [Related]
10. Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Muss HB; Tamura K
Oncologist; 2019 Jul; 24(7):e565-e573. PubMed ID: 30552160
[TBL] [Abstract][Full Text] [Related]
11. Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials.
Li S; Sun S; Xiang H; Yang J; Peng M; Gao Q
Oncoimmunology; 2020; 9(1):1746113. PubMed ID: 32313724
[No Abstract] [Full Text] [Related]
12. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
13. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
[No Abstract] [Full Text] [Related]
14. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events.
Zhao B; Zhao H; Zhao J
J Immunother Cancer; 2018 Oct; 6(1):101. PubMed ID: 30285872
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
[TBL] [Abstract][Full Text] [Related]
16. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
[TBL] [Abstract][Full Text] [Related]
18. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
[TBL] [Abstract][Full Text] [Related]
19. Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis.
Wang X; Wu S; Chen Y; Shao E; Zhuang T; Lu L; Chen X
Front Pharmacol; 2020; 11():5. PubMed ID: 32076409
[TBL] [Abstract][Full Text] [Related]
20. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
[Next] [New Search]